Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is widely distributed in hospital environments, causing serious infections, mainly the bloodstream, surgical site infection and pneumonia. Vancomycin (VAN) is the antibiotic of choice for treating severe MRSA infections; however, nowadays worldwide resistant strains (VRSA), with intermediate susceptibility (VISA) and decreased susceptibility or hetero-resistance to VAN (hVISA) have been reported, related to treatment failure and increased mortality. This report describes the first confirmed isolation of MRSA with hVISA phenotype in a public hospital in Chile.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia
Paper Title
Journal
Date
